TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Intra Uterine Device Insertion in Nulliparous Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Desires IUD placement~* 18 years old or older~* negative pregnancy test~* no prior pregnancies beyond 14 6/7 weeks~* no pelvic inflammatory disease (PID) in last 3 months~* no current cervicitis~* no contraindications to IUD insertion (see exclusion criteria below)~* willing to follow-up in 6-8 weeks for a standard IUD follow-up visit~* Determined by her clinician to be an appropriate candidate for an IUD.~Exclusion Criteria:~* Active cervical infection~* current pregnancy~* prior pregnancy beyond 15 weeks' gestation~* uterine anomaly~* fibroid uterus~* copper allergy/Wilson's disease (for Paragard)~* undiagnosed abnormal uterine bleeding~* cervical or uterine cancer~* allergy to misoprostol (study drug)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Experimental active comparator (Type: EXPERIMENTAL): Drug: Misoprostol~Experimental: 400 mcg taken sublingually 2 hours prior to IUD insertion
- Placebo comparator (Type: PLACEBO_COMPARATOR): Other: Placebo~Pill identical to study drug in appearance, taste, smell. Taken sublingually 2 hours prior to IUD insertion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Female patients 18 years or older at screening~* Female patient is postmenopausal or surgically sterilised~* Patient with locally advanced, metastatic or locally recurrent non-small cell lung cancer with histology of adenocarcinoma~* Nintedanib (Vargatef®) is planned to be prescribed in accordance with the marketing authorisation (SmPC)~* Signed and dated written informed consent in accordance with Good Clinical Practice (GCP) and local legislation prior to admission to the trial~Exclusion criteria:~* Any contraindication to nintedanib (Vargatef®), ethinylestradiol or levonorgestrel (Microgynon®), as specified in the respective labels~* Use of hormone containing contraceptives (including vaginal and intrauterine devices and including hormone replacement therapy) within 30 days prior to first administration of Microgynon®~* Systemic use of drugs known to induce (e.g. rifampicin, St. John's Wort, carbamazepine) or to inhibit (e.g. azole antimycotics, macrolides) CYP3A4 within 7 days prior to first trial drug administration until last pharmacokinetic(PK)-sampling in the trial. Exception: allowed is the intake of corticosteroids as docetaxel (pre)medication~* History of major thrombotic or clinically relevant major bleeding event in the past 6 months~* Persistence of clinically relevant therapy related toxicities (i.e. \> Common Terminology Criteria for Adverse Events \[CTCAE\] grade 2) from previous chemotherapy and/or radiotherapy~* Treatment with other investigational drugs or treatment in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial~* Gastrointestinal disorders or abnormalities that would interfere with absorption of the trial drugs~* Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to first treatment within the trial and without complete wound healing~* Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial~* Patients unable to comply with the protocol~* Previous enrolment in this trial

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All Patients (Type: EXPERIMENTAL): Microgynon alone in Period 1 then with Nintedanib in Period 2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Enrolled in the Canadian avelumab1LM Patient support program (PSP)~* Histologically confirmed diagnosis of stage IV LA/mUC~* No evidence of disease progression following first-line platinum-based chemotherapy~* Receipt of avelumab1LM following 1L platinum-based chemotherapy~* Received the last dose of chemotherapy no more than 10 weeks before entering the PSP~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1~* ≥6 months of follow-up from initiation of AVE 1LM therapy until study end date, unless the patient has died, with known date of death.~Exclusion Criteria:~* Diagnosed with LA/mUC and enrolled in the PSP, but did not receive avelumab~* Pregnancy at index date~* Participation in an interventional clinical trial at any point during the study period~The index date will be considered as the initiation of index therapy. The index therapy will be considered as the avelumab 1LM treatment after 1L platinum-based chemotherapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Canadian Patients with Advanced Urothelial Carcinoma (Type: None): Patients with LA/mUC who following 4-6 cycles of platinum chemotherapy and have not progressed, received avelumab, recommended dose of 10mg/kg body weight intravenously administered over 60 minutes every 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a diagnosis of oligoarticular, polyarticular, psoriatic or enthesitis-related JIA as determined by ILAR criteria. Patients who have been continuously treated with generic sulfasalazine delayed release formulation and have tolerated the product for at least 3 months prior to study enrolment and who are switched to Azulfidine-EN at least 8 days prior to Day 0 are eligible.~* Patients must be at least 6 years of age and has not reached his/her 18th birthday prior to the Baseline Visit (Day 0).~* Onset of JIA must have occurred prior to the patient's 16th birthday.~* Patients must weigh at least 20 kg.~* Patients must be on sulfasalazine 500 mg delayed release tablets and the total daily dose must be within the specified range of 30-60 mg/kg/day with a maximum daily dose of 3 g/day~Exclusion Criteria:~* Patient currently with systemic features of systemic JIA.~* Hypersensitivity to sulfasalazine , its metabolites, sulfonamides or salicylates.~* History of sensitivity to heparin or heparin-induced thrombocytopenia.~* Inability to swallow whole (uncrushed) sulfasalazine 500 mg delayed release tablets as required by protocol

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Sulfasalazine delayed release tablets 30-60 mg/kg/day (divided into BID doses) for 6 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Bioresorbable Vascular Scaffolds Versus Stents in Patients With Chronic Total Occlusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Clinical inclusion criteria:~* Age ≥18 years~* Angina pectoris, equivalent symptoms, and/or positive stress test~* Viable myocardium subtended by chronic total occlusion~* Negative pregnancy test in women with childbearing potential~Angiographic inclusion criteria:~* Chronic total occlusion defined as Thrombolysis in Myocardial Infarction flow 0 with an estimated duration ≥3 months~* Successful wire passage and assumption of successful stent/scaffold deployment~* Target reference vessel diameter 2.5 - 4.0 mm~Exclusion Criteria:~Clinical exclusion criteria:~* Limited long-term prognosis with a life-expectancy \<12 months~* Contraindications to antiplatelet therapy~* Known allergy against cobalt chrome, everolimus, or polylactic acid~Angiographic exclusion criteria:~* Target lesion located in the left main trunk~* Target lesion located in a coronary bypass graft~* Bifurcation lesion with planned two-stent strategy~* Indication for coronary artery bypass grafting

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bioresorbable vascular scaffold (Type: EXPERIMENTAL): Implantation of everolimus-eluting bioresorbable vascular scaffold in chronic total occlusion
- Stent (Type: ACTIVE_COMPARATOR): Implantation everolimus-eluting stent in chronic total occlusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transurethral Vapor Enucleation Resection of the Prostate (TVERP), Bipolar TURis and HoLEP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male, age older than 22 and younger than 75 years of age~2. The patient should be a candidate for surgical treatment of bladder outlet obstruction.~3. Patients with BPH and surgical indication (refractory to medical treatment, refractory or recurrent urinary retention, recurrent haematuria, bladder stones, recurrent infections, hydronephrosis)~4. Prostate volume ˃30 and ≤80 ml~5. PSA \<4 ng/ml in patients above 55 years old and a prostate cancer risk less than 35%. (Prostate cancer risk calculator).~6. IPSS ≥8 (moderate to severe)~7. Indications for TURIS~8. maximum urinary flow (Qmax) \<10ml/second~9. A written informed consent signed by the patient (including patient's agreement to randomization and treatment).~Exclusion Criteria:~1. Patients under anti-inflammatory or steroid therapy~2. Patients under anti-coagulation at a level that could be exposed to a very high risk of complications based on a comprehensive pre-operatory evaluation.~3. Renal insufficiency Serum creatinine (Scr) \>1.5 x upper limit of normal (ULN); AST and ALT\>2.5 x ULN;Total bilirubin \>1.5 x ULN~4. Previous neurogenic lower urinary tract dysfunction.~5. Patients with urethral strictures~6. Severe pulmonary disease and cardio-vascular disorder 、Coagulopathy，and contraindications to anesthesia and surgery.~7. Concurrent participation in any other clinical study~8. Any of the following within the 12 months prior to study: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack and 6 months for deep vein thrombosis or pulmonary embolism.~9. Previous bladder outlet surgery.~10. A clinically significant acute illness.~11. Intake of medication in which the principle investigator considers to preclude enrollment into the trial.~12. Known disease of the central or peripheral nervous system.~13. Any clinical evidence of carcinoma of the prostate.~14. HIV positive or any other immunosuppressive disorder.~15. Psychological/psychiatric disease /Known cognitive disorder.

- Gender: MALE
- Minimum Age: 22 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- TVERP (Type: ACTIVE_COMPARATOR): None
- TURis (Type: ACTIVE_COMPARATOR): None
- HoLEP (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Spinal Cord Stimulation to Treat Post-operative Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients which will be subjected to an OFF-pump CABG procedure~2. More than 18 years of age~3. Subject is able and willing to give informed consent.~Exclusion Criteria:~1. Patients with known history of atrial arrhythmias.~2. Patients who are not treated with β-blockers unless heart rate is too low for β-blockers assumption.~3. Participation in another clinical trial which may affect the outcome within 3 months prior to day of procedure.~4. Other surgical interventions (e.g. valve replacement) programmed in the same surgical session~5. Resting pulse rate ≤45 beats / min as assessed before daily doses of β-blockage is administered.~6. Hypotension (RR systolic \<100 or RR diastolic \<50).~7. Conduction abnormalities on the ECG consisting of a 1st degree atrioventricular block or a complete bundle branch block.~8. Subject is diagnosed with epilepsy or history of seizures.~9. Coagulation abnormalities as determined by anticoagulation guidelines for neuroaxial procedures 2011.~10. Patients not stabilized on an anti-arrhythmic drug regimen for the last 30 days.~11. Patients with long QT syndrome.~12. Patients with Brugada syndrome.~13. Patients affected by Polyneuropathy (e.g. due to diabetes).~14. Patients affected by pericarditis~15. Patients who underwent procedures in the past, which are expected to have changed the innervation of the heart for example:~    * Ablation procedure~   * Cardiac surgery~16. Pregnant patients or nursing (subjects who are of child bearing potential and are not on a reliable form of birth control will undergo a pregnancy test)~17. Patients already implanted with cardiac devices~18. Patients with existing implanted neurostimulators

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional treatment (Type: OTHER): Non interventional group, patients that belong to this arm will receive the conventional treatment for CABG and they will wear the Holter for 5 days.
- Spinal Cord Stimulation System (Type: EXPERIMENTAL): This group will receive the Spinal Cord Stimulation System and they will wear the Holter for 5 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Involved-Field Radiation Therapy in Treating Patients With Previously Untreated Stage I or Stage II Low-Grade Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage I or II, low-grade, non-Hodgkin's lymphoma~  * Follicular lymphoma grade I, II, or III~ * Small lymphocytic lymphoma~ * Lymphoplasmacytoid lymphoma~ * Nodal marginal zone lymphoma~* Previously untreated disease~* At least 1 measurable or evaluable mass at least 1.1 cm (except for patients with stage I disease where the entire mass was removed for diagnostic purposes) NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of indolent or aggressive lymphoma will replace the former terminology of low, intermediate, or high grade lymphoma. However, this protocol uses the former terminology.~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* WHO 0-2~Life expectancy:~* Not specified~Hematopoietic:~* WBC greater than 2,000/mm \^3~* Platelet count greater than 100,000/mm\^3~Hepatic:~* Not specified~Renal:~* Not specified~Other:~* No other prior or concurrent malignancy except basal cell skin cancer or carcinoma in situ of the cervix~* No psychological, familial, sociological, or geographical condition that would preclude study participation~* Not pregnant or nursing~* Fertile patients must use effective contraception~* HIV negative~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* No other concurrent anticancer therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cardiac Tumors in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients in the congenital surgery database~* Children who have been treated for a primary cardiac tumor

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Stress Induced by the COVID-19 Pandemic and Nonconfinement: Study of Anxiety Factors and Potential Effects on Immunity.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult volunteer who agreed to answer the questionnaires~* Age ≥ 18 years old~* Adult affiliated or having a duty to a social security scheme~Exclusion Criteria:~* Children under 18 years old~* Inability to understand information letter, consent, or to use online questionnaire

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Volunteers (Type: None): volunteers over 18 years of age

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Physical Activity Adapted at Home Supervised by Videoconferencing in Post-cancer for Children / AYA Treated for Leukemia (ONCOPED SAPATIC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with Leukemia and followed in intensive post-treatment or with lymphoma and followed in post autologous graft, patient aged 12 to 25 years old (child/AYA), included in the CHU Montpellier and identified by the mobile support team AYA Occitanie-Est, and or the Occitanie-Est Pediatric Division of the Oncology Network of the Occitanie Region,~* Having completed and signed a consent form for the study (Signature of consent by the parents if the patient is a minor)~* affiliated to a safety social regime~Exclusion Criteria:~* Contraindication to the practice of an APA program.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Physical Activity Adapted program (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Peanut Protein Supplementation to Prevent Muscle Atrophy and Improve Recovery Following Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* total knee arthroplasty scheduled within two weeks under the care of surgeons at the Jack Hughston Clinic~Exclusion Criteria:~* history of invasive lower extremity surgery within the last 5 years~* allergy to peanuts or peanut products~* Body Mass Index \<20 or \>35 kg/m2~* currently adhering to a restrictive weight loss diet~* current or recent (within the last 2 months) steroid use~* any physical condition that interferes with performing post-surgery rehabilitation~* known peripheral vascular disease, kidney disease, liver disease, or uncontrolled endocrine disorder~* known overt cardiovascular or metabolic such as heart disease/failure or diabetes~* Radiation exposure within the last 6 months other than dental x-rays or associated with current knee treatment/diagnosis

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Immediate Intervention Group (Type: EXPERIMENTAL): Participants will complete baseline measures and begin daily supplementation of peanut protein powder (72g/day) 7 days prior to total knee arthroplasty until 6 weeks after surgery.
- Wait-llist Control Group (Type: ACTIVE_COMPARATOR): Participants will complete baseline measures 7 days prior to total knee arthroplasty and will receive a 7 week supply after completion of 12 week post-surgery visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues